The unstable repeats-Three evolving faces of neurological disease

Neuron

Volumn 77, Issue 5, 2013, Pages 825-843

  Nelson, David L ^a   Orr, Harry T ^b   Warren, Stephen T ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ALPHA CALCITONIN GENE RELATED PEPTIDE; ANDROGEN RECEPTOR; ANTISENSE OLIGONUCLEOTIDE; ARBACLOFEN; ARGONAUTE 2 PROTEIN; ATAXIN 1; DOXYCYCINE; FACTOR AF2; FRAGILE X MENTAL RETARDATION PROTEIN; MESSENGER RNA; METABOTROPIC RECEPTOR ANTAGONIST; MYOTONIC DYSTROPHY PROTEIN KINASE; OCTAHYDRO 4 HYDROXY 4 [(3 METHYLPHENYL)ETHYNYL] 1H INDOLE 1 CARBOXYLIC ACID METHYL ESTER; PHOSPHOPROTEIN PHOSPHATASE 2A; PLACEBO; POLYGLUTAMINE; POSTSYNAPTIC DENSITY PROTEIN 95; RNA BINDING PROTEIN; RO 4917523; SMALL INTERFERING RNA; STX 107; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG; MICROSATELLITE DNA;

ALLELE; AR GENE; ATXN1 GENE; CGRP1 GENE; CHROMOSOME FRAGILITY; DMPK GENE; EXON; FMRI GENE; FRAGILE X SYNDROME; FRAGILE X TREMOR ATAXIA SYNDROME; GABAERGIC SYSTEM; GAIN OF FUNCTION MUTATION; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC ASSOCIATION; GENOMIC INSTABILITY; HUMAN; HUNTINGTON CHOREA; KENNEDY DISEASE; LOSS OF FUNCTION MUTATION; MICROSATELLITE INSTABILITY; MYOTONIC DYSTROPHY; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NONHUMAN; NUCLEOTIDE REPEAT; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SPINOCEREBELLAR DEGENERATION; TRINUCLEOTIDE REPEAT; ANIMAL; GENETICS;

ANIMALS; BULBO-SPINAL ATROPHY, X-LINKED; FRAGILE X SYNDROME; HUMANS; MICROSATELLITE REPEATS; MYOTONIC DYSTROPHY; NERVOUS SYSTEM DISEASES; SPINOCEREBELLAR ATAXIAS; TRINUCLEOTIDE REPEAT EXPANSION; TRINUCLEOTIDE REPEATS;

MLCS; MLOWN;

EID: 84876449659     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2013.02.022     Document Type: Review

References (242)

1. Antar, L.N., Afroz, R., Dictenberg, J.B., Carroll, R.C., and Bassell, G.J. (2004). Metabotropic glutamate receptor activation regulates fragile x mental retardation protein and FMR1 mRNA localization differentially in dendrites and at synapses. J. Neurosci. 24, 2648-2655.
2. Antar, L.N., Dictenberg, J.B., Plociniak, M., Afroz, R., and Bassell, G.J. (2005). Localization of FMRP-associated mRNA granules and requirement of microtubules for activity-dependent trafficking in hippocampal neurons. Genes Brain Behav. 4, 350-359.
3. Arrasate, M., Mitra, S., Schweitzer, E.S., Segal, M.R., and Finkbeiner, S. (2004). Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431, 805-810.
4. Ascano, M., Jr., Mukherjee, N., Bandaru, P., Miller, J.B., Nusbaum, J.D., Corcoran, D.L., Langlois, C., Munschauer, M., Dewell, S., Hafner, M., et al. (2012). FMRP targets distinct mRNA sequence elements to regulate protein expression. Nature 492, 382-386.
5. Ash, P.E., Bieniek, K.F., Gendron, T.F., Caulfield, T., Lin, W.-L., Dejesus-Hernandez, M., van Blitterswijk, M.M., Jansen-West, K., Paul, J.W., 3rd, Rademakers, R., et al. (2013). Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron. Published online February 12, 2013. http://dx.doi.org/10.1016/j.neuron.2013. 02.004.
6. Ashley, C.T., Jr., Wilkinson, K.D., Reines, D., and Warren, S.T. (1993a). FMR1 protein: conserved RNP family domains and selective RNA binding. Science 262, 563-566.
7. Ashley, C.T., Sutcliffe, J.S., Kunst, C.B., Leiner, H.A., Eichler, E.E., Nelson, D.L., and Warren, S.T. (1993b). Human and murine FMR-1: alternative splicing and translational initiation downstream of the CGG-repeat. Nat. Genet. 4, 244-251.
8. Bagni, C., and Greenough, W.T. (2005). From mRNP trafficking to spine dysmorphogenesis: the roots of fragile X syndrome. Nat. Rev. Neurosci. 6, 376-387.
9. Bagni, C., Tassone, F., Neri, G., and Hagerman, R. (2012). Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics. J. Clin. Invest. 122, 4314-4322.
10. Bardoni, B., Sittler, A., Shen, Y., and Mandel, J.L. (1997). Analysis of domains affecting intracellular localization of the FMRP protein. Neurobiol. Dis. 4, 329-336.
11. Bassell, G.J., and Warren, S.T. (2008). Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron 60, 201-214.
12. Bear, M.F., Huber, K.M., and Warren, S.T. (2004). The mGluR theory of fragile X mental retardation. Trends Neurosci. 27, 370-377.
13. Bechara, E.G., Didiot, M.C., Melko, M., Davidovic, L., Bensaid, M., Martin, P., Castets, M., Pognonec, P., Khandjian, E.W., Moine, H., and Bardoni, B. (2009). A novel function for fragile X mental retardation protein in translational activation. PLoS Biol. 7, e16.
14. Berry-Kravis, E.M., Hessl, D., Rathmell, B., Zarevics, P., Cherubini, M., Walton-Bowen, K., Mu, Y., Nguyen, D.V., Gonzalez-Heydrich, J., Wang, P.P., Carpenter, R.L., Bear, M.F., and Hagerman, R.J. (2012). Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci. Transl. Med. 4, 152ra127.
15. Berul, C.I., Maguire, C.T., Aronovitz, M.J., Greenwood, J., Miller, C., Gehrmann, J., Housman, D., Mendelsohn, M.E., and Reddy, S. (1999). DMPK dosage alterations result in atrioventricular conduction abnormalities in a mouse myotonic dystrophy model. J. Clin. Invest. 103, R1-R7.
16. Bhakar, A.L., Dölen, G., and Bear, M.F. (2012). The pathophysiology of fragile X (and what it teaches us about synapses). Annu. Rev. Neurosci. 35, 417-443.
17. Bolduc, F.V., Bell, K., Cox, H., Broadie, K.S., and Tully, T. (2008). Excess protein synthesis in Drosophila fragile X mutants impairs long-term memory. Nat. Neurosci. 11, 1143-1145.
18. Bontekoe, C.J., de Graaff, E., Nieuwenhuizen, I.M., Willemsen, R., and Oostra, B.A. (1997). FMR1 premutation allele (CGG)81 is stable in mice. Eur. J. Hum. Genet. 5, 293-298.
19. Boudreau, R.L., Martins, I., and Davidson, B.L. (2009). Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. Mol. Ther. 17, 169-175.
20. Bozdagi, O., Sakurai, T., Dorr, N., Pilorge, M., Takahashi, N., and Buxbaum, J.D. (2012). Haploinsufficiency of Cyfip1 produces fragile X-like phenotypes in mice. PLoS ONE 7, e42422.
21. Brook, J.D., McCurrach, M.E., Harley, H.G., Buckler, A.J., Church, D., Aburatani, H., Hunter, K., Stanton, V.P., Thirion, J.P., Hudson, T., et al. (1992). Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 30 end of a transcript encoding a protein kinase family member. Cell 68, 799-808.
22. Brouwer, J.R., Severijnen, E., de Jong, F.H., Hessl, D., Hagerman, R.J., Oostra, B.A., and Willemsen, R. (2008). Altered hypothalamus-pituitaryadrenal gland axis regulation in the expanded CGG-repeat mouse model for fragile X-associated tremor/ataxia syndrome. Psychoneuroendocrinology 33, 863-873.
23. Brown, V., Jin, P., Ceman, S., Darnell, J.C., O'Donnell, W.T., Tenenbaum, S.A., Jin, X., Feng, Y., Wilkinson, K.D., Keene, J.D., et al. (2001). Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell 107, 477-487.
24. Burright, E.N., Clark, H.B., Servadio, A., Matilla, T., Feddersen, R.M., Yunis, W.S., Duvick, L.A., Zoghbi, H.Y., and Orr, H.T. (1995). SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell 82, 937-948.
25. Caudy, A.A., Myers, M., Hannon, G.J., and Hammond, S.M. (2002). Fragile X-related protein and VIG associate with the RNA interference machinery. Genes Dev. 16, 2491-2496.
26. Ceman, S., O'Donnell, W.T., Reed, M., Patton, S., Pohl, J., and Warren, S.T. (2003). Phosphorylation influences the translation state of FMRP-associated polyribosomes. Hum. Mol. Genet. 12, 3295-3305.
27. Chang, S., Bray, S.M., Li, Z., Zarnescu, D.C., He, C., Jin, P., and Warren, S.T. (2008). Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila. Nat. Chem. Biol. 4, 256-263.
28. Charizanis, K., Lee, K.Y., Batra, R., Goodwin, M., Zhang, C., Yuan, Y., Shiue, L., Cline, M., Scotti, M.M., Xia, G., et al. (2012). Muscleblind-like 2-mediated alternative splicing in the developing brain and dysregulation in myotonic dystrophy. Neuron 75, 437-450.
29. Chen, H.K., Fernandez-Funez, P., Acevedo, S.F., Lam, Y.C., Kaytor, M.D., Fernandez, M.H., Aitken, A., Skoulakis, E.M., Orr, H.T., Botas, J., and Zoghbi, H.Y. (2003a). Interaction of Akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1. Cell 113, 457-468.
30. Chen, L., Yun, S.W., Seto, J., Liu, W., and Toth, M. (2003b). The fragile X mental retardation protein binds and regulates a novel class of mRNAs containing U rich target sequences. Neuroscience 120, 1005-1017.
31. Chen, Y.W., Allen, M.D., Veprintsev, D.B., Löwe, J., and Bycroft, M. (2004). The structure of the AXH domain of spinocerebellar ataxin-1. J. Biol. Chem. 279, 3758-3765.
32. Chevalier-Larsen, E.S., O'Brien, C.J., Wang, H., Jenkins, S.C., Holder, L., Lieberman, A.P., and Merry, D.E. (2004). Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy. J. Neurosci. 24, 4778-4786.
33. Chico, L.K., Van Eldik, L.J., and Watterson, D.M. (2009). Targeting protein kinases in central nervous system disorders. Nat. Rev. Drug Discov. 8, 892-909.
34. Childs-Disney, J.L., Hoskins, J., Rzuczek, S.G., Thornton, C.A., and Disney, M.D. (2012a). Rationally designed small molecules targeting the RNA that causes myotonic dystrophy type 1 are potently bioactive. ACS Chem. Biol. 7, 856-862.
35. Childs-Disney, J.L., Parkesh, R., Nakamori, M., Thornton, C.A., and Disney, M.D. (2012b). Rational design of bioactive, modularly assembled aminoglycosides targeting the RNA that causes myotonic dystrophy type 1. ACS Chem. Biol. 7, 1984-1993.
36. Coffee, B., Zhang, F., Warren, S.T., and Reines, D. (1999). Acetylated histones are associated with FMR1 in normal but not fragile X-syndrome cells. Nat. Genet. 22, 98-101.
37. Coffee, B., Zhang, F., Ceman, S., Warren, S.T., and Reines, D. (2002). Histone modifications depict an aberrantly heterochromatinized FMR1 gene in fragile x syndrome. Am. J. Hum. Genet. 71, 923-932.
38. Coffee, B., Ikeda, M., Budimirovic, D.B., Hjelm, L.N., Kaufmann, W.E., and Warren, S.T. (2008). Mosaic FMR1 deletion causes fragile X syndrome and can lead to molecular misdiagnosis: a case report and review of the literature. Am. J. Med. Genet. A. 146A, 1358-1367.
39. Collins, S.C., Bray, S.M., Suhl, J.A., Cutler, D.J., Coffee, B., Zwick, M.E., and Warren, S.T. (2010). Identification of novel FMR1 variants by massively parallel sequencing in developmentally delayed males. Am. J. Med. Genet. A. 152A, 2512-2520.
40. Conway, G.S., Payne, N.N., Webb, J., Murray, A., and Jacobs, P.A. (1998). Fragile X premutation screening in women with premature ovarian failure. Hum. Reprod. 13, 1184-1187.
41. Cummings, C.J., Reinstein, E., Sun, Y., Antalffy, B., Jiang, Y., Ciechanover, A., Orr, H.T., Beaudet, A.L., and Zoghbi, H.Y. (1999). Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron 24, 879-892.
42. Curia, G., Papouin, T., Séguéla, P., and Avoli, M. (2009). Downregulation of tonic GABAergic inhibition in a mouse model of fragile X syndrome. Cereb. Cortex 19, 1515-1520.
43. Cvetanovic, M., Patel, J., Kini, A., Hugo, V., and Opal, P. (2011). Vascular endothelial growth factor ameliorates the ataxic phenotype in a mouse model of spinocerebellar ataxia type 1. Nat. Med. 17, 1445-1447.
44. D'Hulst, C., De Geest, N., Reeve, S.P., Van Dam, D., De Deyn, P.P., Hassan, B.A., and Kooy, R.F. (2006). Decreased expression of the GABAA receptor in fragile X syndrome. Brain Res. 1121, 238-245.
45. D'Hulst, C., Heulens, I., Brouwer, J.R., Willemsen, R., De Geest, N., Reeve, S.P., De Deyn, P.P., Hassan, B.A., and Kooy, R.F. (2009). Expression of the GABAergic system in animal models for fragile X syndrome and fragile X associated tremor/ataxia syndrome (FXTAS). Brain Res. 1253, 176-183.
46. Darnell, J.C., Jensen, K.B., Jin, P., Brown, V., Warren, S.T., and Darnell, R.B. (2001). Fragile X mental retardation protein targets Gquartet mRNAs important for neuronal function. Cell 107, 489-499.
47. Darnell, J.C., Fraser, C.E., Mostovetsky, O., Stefani, G., Jones, T.A., Eddy, S.R., and Darnell, R.B. (2005). Kissing complex RNAs mediate interaction between the Fragile-X mental retardation protein KH2 domain and brain polyribosomes. Genes Dev. 19, 903-918.
48. Darnell, J.C., Van Driesche, S.J., Zhang, C., Hung, K.Y., Mele, A., Fraser, C.E., Stone, E.F., Chen, C., Fak, J.J., Chi, S.W., et al. (2011). FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 146, 247-261.
49. De Boulle, K., Verkerk, A.J., Reyniers, E., Vits, L., Hendrickx, J., Van Roy, B., Van den Bos, F., de Graaff, E., Oostra, B.A., and Willems, P.J. (1993). A point mutation in the FMR-1 gene associated with fragile X mental retardation. Nat. Genet. 3, 31-35.
50. De Chiara, C., Menon, R.P., Strom, M., Gibson, T.J., and Pastore, A. (2009). Phosphorylation of S776 and 14-3-3 binding modulate ataxin-1 interaction with splicing factors. PLoS ONE 4, e8372.
51. De Diego Otero, Y., Severijnen, L.A., van Cappellen, G., Schrier, M., Oostra, B., and Willemsen, R. (2002). Transport of fragile X mental retardation protein via granules in neurites of PC12 cells. Mol. Cell. Biol. 22, 8332-8341.
52. De Haro, M., Al-Ramahi, I., De Gouyon, B., Ukani, L., Rosa, A., Faustino, N.A., Ashizawa, T., Cooper, T.A., and Botas, J. (2006). MBNL1 and CUGBP1 modify expanded CUG-induced toxicity in a Drosophila model of myotonic dystrophy type 1. Hum. Mol. Genet. 15, 2138-2145.
53. DeJesus-Hernandez, M., Mackenzie, I.R., Boeve, B.F., Boxer, A.L., Baker, M., Rutherford, N.J., Nicholson, A.M., Finch, N.A., Flynn, H., Adamson, J., et al. (2011). Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245-256.
54. Deng, P.Y., Rotman, Z., Blundon, J.A., Cho, Y., Cui, J., Cavalli, V., Zakharenko, S.S., and Klyachko, V.A. (2013). FMRP regulates neurotransmitter release and synaptic information transmission by modulating action potential duration via BK channels. Neuron 77, 696-711.
55. Devys, D., Lutz, Y., Rouyer, N., Bellocq, J.P., and Mandel, J.L. (1993). The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation. Nat. Genet. 4, 335-340.
56. Disney, M.D., Liu, B., Yang, W.-Y., Sellier, C., Tran, T., Charlet-Berguerand, N., and Childs-Disney, J.L. (2012). A small molecule that targets r(CGG)(exp) and improves defects in fragile X-associated tremor ataxia syndrome. ACS Chem. Biol. 7, 1711-1718.
57. Dölen, G., Osterweil, E., Rao, B.S., Smith, G.B., Auerbach, B.D., Chattarji, S., and Bear, M.F. (2007). Correction of fragile X syndrome in mice. Neuron 56, 955-962.
58. Du, H., Cline, M.S., Osborne, R.J., Tuttle, D.L., Clark, T.A., Donohue, J.P., Hall, M.P., Shiue, L., Swanson, M.S., Thornton, C.A., and Ares, M., Jr. (2010). Aberrant alternative splicing and extracellular matrix gene expression in mouse models of myotonic dystrophy. Nat. Struct. Mol. Biol. 17, 187-193.
59. Duvick, L., Barnes, J., Ebner, B., Agrawal, S., Andresen, M., Lim, J., Giesler, G.J., Zoghbi, H.Y., and Orr, H.T. (2010). SCA1-like disease in mice expressing wild-type ataxin-1 with a serine to aspartic acid replacement at residue 776. Neuron 67, 929-935.
60. Eberhart, D.E., Malter, H.E., Feng, Y., and Warren, S.T. (1996). The fragile X mental retardation protein is a ribonucleoprotein containing both nuclear localization and nuclear export signals. Hum. Mol. Genet. 5, 1083-1091.
61. Echeverria, G.V., and Cooper, T.A. (2012). RNA-binding proteins in microsatellite expansion disorders: mediators of RNA toxicity. Brain Res. 1462, 100-111.
62. Eichler, E.E., Richards, S., Gibbs, R.A., and Nelson, D.L. (1993). Fine structure of the human FMR1 gene. Hum. Mol. Genet. 2, 1147-1153.
63. Eichler, E.E., Holden, J.J., Popovich, B.W., Reiss, A.L., Snow, K., Thibodeau, S.N., Richards, C.S., Ward, P.A., and Nelson, D.L. (1994). Length of uninterrupted CGG repeats determines instability in the FMR1 gene. Nat. Genet. 8, 88-94.
64. Emamian, E.S., Kaytor, M.D., Duvick, L.A., Zu, T., Tousey, S.K., Zoghbi, H.Y., Clark, H.B., and Orr, H.T. (2003). Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice. Neuron 38, 375-387.
65. Fähling, M., Mrowka, R., Steege, A., Kirschner, K.M., Benko, E., Förstera, B., Persson, P.B., Thiele, B.J., Meier, J.C., and Scholz, H. (2009). Translational regulation of the human achaete-scute homologue-1 by fragile X mental retardation protein. J. Biol. Chem. 284, 4255-4266.
66. Fardaei, M., Larkin, K., Brook, J.D., and Hamshere, M.G. (2001). In vivo colocalisation of MBNL protein with DMPK expanded-repeat transcripts. Nucleic Acids Res. 29, 2766-2771.
67. Feng, Y., Absher, D., Eberhart, D.E., Brown, V., Malter, H.E., and Warren, S.T. (1997a). FMRP associates with polyribosomes as an mRNP, and the I304N mutation of severe fragile X syndrome abolishes this association. Mol. Cell 1, 109-118.
68. Feng, Y., Gutekunst, C.A., Eberhart, D.E., Yi, H., Warren, S.T., and Hersch, S.M. (1997b). Fragile X mental retardation protein: nucleocytoplasmic shuttling and association with somatodendritic ribosomes. J. Neurosci. 17, 1539-1547.
69. François, V., Klein, A.F., Beley, C., Jollet, A., Lemercier, C., Garcia, L., and Furling, D. (2011). Selective silencing of mutated mRNAs in DM1 by using modified hU7-snRNAs. Nat. Struct. Mol. Biol. 18, 85-87.
70. Fryer, J.D., Yu, P., Kang, H., Mandel-Brehm, C., Carter, A.N., Crespo-Barreto, J., Gao, Y., Flora, A., Shaw, C., Orr, H.T., and Zoghbi, H.Y. (2011). Exercise and genetic rescue of SCA1 via the transcriptional repressor Capicua. Science 334, 690-693.
71. Fu, Y.H., Kuhl, D.P., Pizzuti, A., Pieretti, M., Sutcliffe, J.S., Richards, S., Verkerk, A.J., Holden, J.J., Fenwick, R.G., Jr., Warren, S.T., et al. (1991). Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell 67, 1047-1058.
72. Fu, Y.H., Pizzuti, A., Fenwick, R.G., Jr., King, J., Rajnarayan, S., Dunne, P.W., Dubel, J., Nasser, G.A., Ashizawa, T., de Jong, P., et al. (1992). An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science 255, 1256-1258.
73. Gantois, I., Vandesompele, J., Speleman, F., Reyniers, E., D'Hooge, R., Severijnen, L.A., Willemsen, R., Tassone, F., and Kooy, R.F. (2006). Expression profiling suggests underexpression of the GABA(A) receptor subunit delta in the fragile X knockout mouse model. Neurobiol. Dis. 21, 346-357.
74. García-López, A., Llamusí, B., Orzáez, M., Pérez-Payá, E., and Artero, R.D. (2011). In vivo discovery of a peptide that prevents CUG-RNA hairpin formation and reverses RNA toxicity in myotonic dystrophy models. Proc. Natl. Acad. Sci. USA 108, 11866-11871.
75. Gehrking, K.M., Andresen, J.M., Duvick, L., Lough, J., Zoghbi, H.Y., and Orr, H.T. (2011). Partial loss of Tip60 slows midstage neurodegeneration in a spinocerebellar ataxia type 1 (SCA1) mouse model. Hum. Mol. Genet. 20, 2204-2212.
76. Greco, C.M., Hageman, R.J., Tassone, F., Chudley, A.E., Del Bigio, M.R., Jacquemont, S., Leehey, M., and Hagerman, P.J. (2002). Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers. Brain 125, 1760-1771.
77. Greco, C.M., Berman, R.F., Martin, R.M., Tassone, F., Schwartz, P.H., Chang, A., Trapp, B.D., Iwahashi, C., Brunberg, J., Grigsby, J., et al. (2006). Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS). Brain 129, 243-255.
78. Greenough, W.T., Klintsova, A.Y., Irwin, S.A., Galvez, R., Bates, K.E., and Weiler, I.J. (2001). Synaptic regulation of protein synthesis and the fragile X protein. Proc. Natl. Acad. Sci. USA 98, 7101-7106.
79. Grønskov, K., Brøndum-Nielsen, K., Dedic, A., and Hjalgrim, H. (2011). A nonsense mutation in FMR1 causing fragile X syndrome. Eur. J. Hum. Genet. 19, 489-491.
80. Gross, C., Yao, X., Pong, D.L., Jeromin, A., and Bassell, G.J. (2011). Fragile X mental retardation protein regulates protein expression and mRNA translation of the potassium channel Kv4.2. J. Neurosci. 31, 5693-5698.
81. Gu, X., Greiner, E.R., Mishra, R., Kodali, R., Osmand, A., Finkbeiner, S., Steffan, J.S., Thompson, L.M., Wetzel, R., and Yang, X.W. (2009). Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice. Neuron 64, 828-840.
82. Hagerman, R.J., Leehey, M., Heinrichs, W., Tassone, F., Wilson, R., Hills, J., Grigsby, J., Gage, B., and Hagerman, P.J. (2001). Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 57, 127-130.
83. Haines, J.L., Schut, L.J., Weitkamp, L.R., Thayer, M., and Anderson, V.E. (1984). Spinocerebellar ataxia in a large kindred: age at onset, reproduction, and genetic linkage studies. Neurology 34, 1542-1548.
84. Hamilton, B.A., Frankel, W.N., Kerrebrock, A.W., Hawkins, T.L., FitzHugh, W., Kusumi, K., Russell, L.B., Mueller, K.L., van Berkel, V., Birren, B.W., et al. (1996). Disruption of the nuclear hormone receptor RORa in staggerer mice. Nature 379, 736-739.
85. Hampson, D.R., Adusei, D.C., and Pacey, L.K. (2011). The neurochemical basis for the treatment of autism spectrum disorders and Fragile X Syndrome. Biochem. Pharmacol. 81, 1078-1086.
86. Harper, P.S. (1989). Myotonic Dystrophy, 2 Edn. (Philadelphia: WB Saunders).
87. Harper, P.S., Harley, H.G., Reardon, W., and Shaw, D.J. (1992). Anticipation in myotonic dystrophy: new light on an old problem. Am. J. Hum. Genet. 51, 10-16.
88. Hashem, V., Galloway, J.N., Mori, M., Willemsen, R., Oostra, B.A., Paylor, R., and Nelson, D.L. (2009). Ectopic expression of CGG containing mRNA is neurotoxic in mammals. Hum. Mol. Genet. 18, 2443-2451.
89. Hearst, S.M., Lopez, M.E., Shao, Q., Liu, Y., and Vig, P.J. (2010). Dopamine D2 receptor signaling modulates mutant ataxin-1 S776 phosphorylation and aggregation. J. Neurochem. 114, 706-716.
90. Heitz, D., Rousseau, F., Devys, D., Saccone, S., Abderrahim, H., Le Paslier, D., Cohen, D., Vincent, A., Toniolo, D., Della Valle, G., et al. (1991). Isolation of sequences that span the fragile X and identification of a fragile X-related CpG island. Science 251, 1236-1239.
91. Henderson, C., Wijetunge, L., Kinoshita, M.N., Shumway, M., Hammond, R.S., Postma, F.R., Brynczka, C., Rush, R., Thomas, A., Paylor, R., Warren, S.T., Vanderklish, P.W., Kind, P.C., Carpenter, R.L., Bear, M.F., and Healy, A.M. (2012). Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABA(B) receptors with arbaclofen. Sci. Transl. Med. 4, 152ra128.
92. Hokkanen, S., Feldmann, H.M., Ding, H., Jung, C.K., Bojarski, L., Renner-Müller, I., Schüller, U., Kretzschmar, H., Wolf, E., and Herms, J. (2012). Lack of Pur-alpha alters postnatal brain development and causes megalencephaly. Hum. Mol. Genet. 21, 473-484.
93. Hong, S., Ka, S., Kim, S., Park, Y., and Kang, S. (2003). p80 coilin, a coiled body-specific protein, interacts with ataxin-1, the SCA1 gene product. Biochim. Biophys. Acta 1638, 35-42.
94. Huber, K.M., Roder, J.C., and Bear, M.F. (2001). Chemical induction of mGluR5- and protein synthesis-dependent long-term depression in hippocampal area CA1. J. Neurophysiol. 86, 321-325.
95. Huber, K.M., Gallagher, S.M., Warren, S.T., and Bear, M.F. (2002). Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc. Natl. Acad. Sci. USA 99, 7746-7750.
96. Humbert, S., Bryson, E.A., Cordelieres, E.P., Connors, N.C., Datta, S.R., Finkbeiner, S., Greenberg, M.E., and Saudou, F. (2002). The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev. Cell 2, 831-837.
97. Huttlin, E.L., Jedrychowski, M.P., Elias, J.E., Goswami, T., Rad, R., Beausoleil, S.A., Villén, J., Haas, W., Sowa, M.E., and Gygi, S.P. (2010). A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143, 1174-1189.
98. Iliff, A.J., Renoux, A.J., Krans, A., Usdin, K., Sutton, M.A., and Todd, P.K. (2013). Impaired activity-dependent FMRP translation and enhanced mGluR-dependent LTD in Fragile X premutation mice. Hum. Mol. Genet. 22, 1180-1192.
99. Iossifov, I., Ronemus, M., Levy, D., Wang, Z., Hakker, I., Rosenbaum, J., Yamrom, B., Lee, Y.H., Narzisi, G., Leotta, A., et al. (2012). De novo gene disruptions in children on the autistic spectrum. Neuron 74, 285-299.
100. Irwin, S., Vandelft, M., Pinchev, D., Howell, J.L., Graczyk, J., Orr, H.T., and Truant, R. (2005). RNA association and nucleocytoplasmic shuttling by ataxin-1. J. Cell Sci. 118, 233-242.
101. Ishizuka, A., Siomi, M.C., and Siomi, H. (2002). A Drosophila fragile X protein interacts with components of RNAi and ribosomal proteins. Genes Dev. 16, 2497-2508.
102. Iwahashi, C.K., Yasui, D.H., An, H.J., Greco, C.M., Tassone, F., Nannen, K., Babineau, B., Lebrilla, C.B., Hagerman, R.J., and Hagerman, P.J. (2006). Protein composition of the intranuclear inclusions of FXTAS. Brain 129, 256-271.
103. Jacobs, P.A., Glover, T.W., Mayer, M., Fox, P., Gerrard, J.W., Dunn, H.G., and Herbst, D.S. (1980). X-linked mental retardation: a study of 7 families. Am. J. Med. Genet. 7, 471-489.
104. Jacquemont, S., Hagerman, R.J., Leehey, M., Grigsby, J., Zhang, L., Brunberg, J.A., Greco, C., Des Portes, V., Jardini, T., Levine, R., et al. (2003). Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am. J. Hum. Genet. 72, 869-878.
105. Jacquemont, S., Hagerman, R.J., Leehey, M.A., Hall, D.A., Levine, R.A., Brunberg, J.A., Zhang, L., Jardini, T., Gane, L.W., Harris, S.W., et al. (2004). Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population. JAMA 291, 460-469.
106. Jacquemont, S., Curie, A., des Portes, V., Torrioli, M.G., Berry-Kravis, E., Hagerman, R.J., Ramos, F.J., Cornish, K., He, Y., Paulding, C., et al. (2011). Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci. Transl. Med. 3, ra1.
107. Jafar-Nejad, P., Ward, C.S., Richman, R., Orr, H.T., and Zoghbi, H.Y. (2011). Regional rescue of spinocerebellar ataxia type 1 phenotypes by 14-3-3ε haploinsufficiency in mice underscores complex pathogenicity in neurodegeneration. Proc. Natl. Acad. Sci. USA 108, 2142-2147.
108. Jin, P., Zarnescu, D.C., Zhang, F., Pearson, C.E., Lucchesi, J.C., Moses, K., and Warren, S.T. (2003). RNA-mediated neurodegeneration caused by the fragile X premutation rCGG repeats in Drosophila. Neuron 39, 739-747.
109. Jin, P., Zarnescu, D.C., Ceman, S., Nakamoto, M., Mowrey, J., Jongens, T.A., Nelson, D.L., Moses, K., and Warren, S.T. (2004). Biochemical and genetic interaction between the fragile X mental retardation protein and the microRNA pathway. Nat. Neurosci. 7, 113-117.
110. Jin, P., Duan, R., Qurashi, A., Qin, Y., Tian, D., Rosser, T.C., Liu, H., Feng, Y., and Warren, S.T. (2007). Pur alpha binds to rCGG repeats and modulates repeat-mediated neurodegeneration in a Drosophila model of fragile X tremor/ataxia syndrome. Neuron 55, 556-564.
111. Jorgensen, N.D., Andresen, J.M., Lagalwar, S., Armstrong, B., Stevens, S., Byam, C.E., Duvick, L.A., Lai, S., Jafar-Nejad, P., Zoghbi, H.Y., et al. (2009). Phosphorylation of ATXN1 at Ser776 in the cerebellum. J. Neurochem. 110, 675-686.
112. Kalsotra, A., Xiao, X., Ward, A.J., Castle, J.C., Johnson, J.M., Burge, C.B., and Cooper, T.A. (2008). A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart. Proc. Natl. Acad. Sci. USA 105, 20333-20338.
113. Kanadia, R.N., Johnstone, K.A., Mankodi, A., Lungu, C., Thornton, C.A., Esson, D., Timmers, A.M., Hauswirth, W.W., and Swanson, M.S. (2003). A muscleblind knockout model for myotonic dystrophy. Science 302, 1978-1980.
114. Kanadia, R.N., Shin, J., Yuan, Y., Beattie, S.G., Wheeler, T.M., Thornton, C.A., and Swanson, M.S. (2006). Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy. Proc. Natl. Acad. Sci. USA 103, 11748-11753.
115. Katsuno, M., Adachi, H., Kume, A., Li, M., Nakagomi, Y., Niwa, H., Sang, C., Kobayashi, Y., Doyu, M., and Sobue, G. (2002). Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 35, 843-854.
116. Kennedy, W.R., Alter, M., and Sung, J.H. (1968). Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. Neurology 18, 671-680.
117. Kenneson, A., Zhang, F., Hagedorn, C.H., and Warren, S.T. (2001). Reduced FMRP and increased FMR1 transcription is proportionally associated with CGG repeat number in intermediate-length and premutation carriers. Hum. Mol. Genet. 10, 1449-1454.
118. Khalili, K., Del Valle, L., Muralidharan, V., Gault, W.J., Darbinian, N., Otte, J., Meier, E., Johnson, E.M., Daniel, D.C., Kinoshita, Y., et al. (2003). Puralpha is essential for postnatal brain development and developmentally coupled cellular proliferation as revealed by genetic inactivation in the mouse. Mol. Cell. Biol. 23, 6857-6875.
119. Khandjian, E.W., Huot, M.E., Tremblay, S., Davidovic, L., Mazroui, R., and Bardoni, B. (2004). Biochemical evidence for the association of fragile X mental retardation protein with brain polyribosomal ribonucleoparticles. Proc. Natl. Acad. Sci. USA 101, 13357-13362.
120. Kiebler, M.A., and Bassell, G.J. (2006). Neuronal RNA granules: movers and makers. Neuron 51, 685-690.
121. Kim, M., Bellini, M., and Ceman, S. (2009). Fragile X mental retardation protein FMRP binds mRNAs in the nucleus. Mol. Cell. Biol. 29, 214-228.
122. King-Jones, K., and Thummel, C.S. (2005). Nuclear receptors-a perspective from Drosophila. Nat. Rev. Genet. 6, 311-323.
123. Klement, I.A., Skinner, P.J., Kaytor, M.D., Yi, H., Hersch, S.M., Clark, H.B., Zoghbi, H.Y., and Orr, H.T. (1998). Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 95, 41-53.
124. Kobayashi, H., Abe, K., Matsuura, T., Ikeda, Y., Hitomi, T., Akechi, Y., Habu, T., Liu, W., Okuda, H., and Koizumi, A. (2011). Expansion of intronic GGCCTG hexanucleotide repeat in NOP56 causes SCA36, a type of spinocerebellar ataxia accompanied by motor neuron involvement. Am. J. Hum. Genet. 89, 121-130.
125. Kordasiewicz, H.B., Stanek, L.M., Wancewicz, E.V., Mazur, C., McAlonis, M.M., Pytel, K.A., Artates, J.W., Weiss, A., Cheng, S.H., Shihabuddin, L.S., et al. (2012). Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 74, 1031-1044.
126. Kratter, I.H., and Finkbeiner, S. (2010). PolyQ disease: too many Qs, too much function? Neuron 67, 897-899.
127. Kremer, E.J., Pritchard, M., Lynch, M., Yu, S., Holman, K., Baker, E., Warren, S.T., Schlessinger, D., Sutherland, G.R., and Richards, R.I. (1991). Mapping of DNA instability at the fragile X to a trinucleotide repeat sequence p(CCG)n. Science 252, 1711-1714.
128. Krichevsky, A.M., and Kosik, K.S. (2001). Neuronal RNA granules: a link between RNA localization and stimulation-dependent translation. Neuron 32, 683-696.
129. Krueger, D.D., and Bear, M.F. (2011). Toward fulfilling the promise of molecular medicine in fragile X syndrome. Annu. Rev. Med. 62, 411-429.
130. Kunst, C.B., and Warren, S.T. (1994). Cryptic and polar variation of the fragile X repeat could result in predisposing normal alleles. Cell 77, 853-861.
131. La Spada, A.R., and Taylor, J.P. (2010). Repeat expansion disease: progress and puzzles in disease pathogenesis. Nat. Rev. Genet. 11, 247-258.
132. La Spada, A.R., Wilson, E.M., Lubahn, D.B., Harding, A.E., and Fischbeck, K.H. (1991). Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352, 77-79.
133. Laggerbauer, B., Ostareck, D., Keidel, E.M., Ostareck-Lederer, A., and Fischer, U. (2001). Evidence that fragile X mental retardation protein is a negative regulator of translation. Hum. Mol. Genet. 10, 329-338.
134. Lai, S., O'Callaghan, B., Zoghbi, H.Y., and Orr, H.T. (2011). 14-3-3 Binding to ataxin-1(ATXN1) regulates its dephosphorylation at Ser-776 and transport to the nucleus. J. Biol. Chem. 286, 34606-34616.
135. Lam, Y.C., Bowman, A.B., Jafar-Nejad, P., Lim, J., Richman, R., Fryer, J.D., Hyun, E.D., Duvick, L.A., Orr, H.T., Botas, J., and Zoghbi, H.Y. (2006). ATAXIN-1 interacts with the repressor Capicua in its native complex to cause SCA1 neuropathology. Cell 127, 1335-1347.
136. Lavedan, C., Grabczyk, E., Usdin, K., and Nussbaum, R.L. (1998). Long uninterrupted CGG repeats within the first exon of the human FMR1 gene are not intrinsically unstable in transgenic mice. Genomics 50, 229-240.
137. Lee, J.E., Bennett, C.F., and Cooper, T.A. (2012). RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1. Proc. Natl. Acad. Sci. USA 109, 4221-4226.
138. Lim, J., Crespo-Barreto, J., Jafar-Nejad, P., Bowman, A.B., Richman, R., Hill, D.E., Orr, H.T., and Zoghbi, H.Y. (2008). Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1. Nature 452, 713-718.
139. Lima, W.F., Prakash, T.P., Murray, H.M., Kinberger, G.A., Li, W., Chappell, A.E., Li, C.S., Murray, S.F., Gaus, H., Seth, P.P., et al. (2012). Single-stranded siRNAs activate RNAi in animals. Cell 150, 883-894.
140. Lin, X., Miller, J.W., Mankodi, A., Kanadia, R.N., Yuan, Y., Moxley, R.T., Swanson, M.S., and Thornton, C.A. (2006). Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Hum. Mol. Genet. 15, 2087-2097.
141. Liquori, C.L., Ricker, K., Moseley, M.L., Jacobsen, J.F., Kress, W., Naylor, S.L., Day, J.W., and Ranum, L.P. (2001). Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 293, 864-867.
142. Lorenzetti, D., Watase, K., Xu, B., Matzuk, M.M., Orr, H.T., and Zoghbi, H.Y. (2000). Repeat instability and motor incoordination in mice with a targeted expanded CAG repeat in the Sca1 locus. Hum. Mol. Genet. 9, 779-785.
143. Lubs, H.A. (1969). A marker X chromosome. Am. J. Hum. Genet. 21, 231-244.
144. Lugenbeel, K.A., Peier, A.M., Carson, N.L., Chudley, A.E., and Nelson, D.L. (1995). Intragenic loss of function mutations demonstrate the primary role of FMR1 in fragile X syndrome. Nat. Genet. 10, 483-485.
145. Mahadevan, M.S. (2012). Myotonic dystrophy: is a narrow focus obscuring the rest of the field? Curr. Opin. Neurol. 25, 609-613.
146. Mahadevan, M., Tsilfidis, C., Sabourin, L., Shutler, G., Amemiya, C., Jansen, G., Neville, C., Narang, M., Barceló, J., O'Hoy, K., et al. (1992). Myotonic dystrophy mutation: an unstable CTG repeat in the 30 untranslated region of the gene. Science 255, 1253-1255.
147. Mahadevan, M.S., Yadava, R.S., Yu, Q., Balijepalli, S., Frenzel-McCardell, C.D., Bourne, T.D., and Phillips, L.H. (2006). Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy. Nat. Genet. 38, 1066-1070.
148. Malter, H.E., Iber, J.C., Willemsen, R., de Graaff, E., Tarleton, J.C., Leisti, J., Warren, S.T., and Oostra, B.A. (1997). Characterization of the full fragile X syndrome mutation in fetal gametes. Nat. Genet. 15, 165-169.
149. Mankodi, A., Logigian, E., Callahan, L., McClain, C., White, R., Henderson, D., Krym, M., and Thornton, C.A. (2000). Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science 289, 1769-1773.
150. Mankodi, A., Urbinati, C.R., Yuan, Q.P., Moxley, R.T., Sansone, V., Krym, M., Henderson, D., Schalling, M., Swanson, M.S., and Thornton, C.A. (2001). Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2. Hum. Mol. Genet. 10, 2165-2170.
151. Marteyn, A., Maury, Y., Gauthier, M.M., Lecuyer, C., Vernet, R., Denis, J.A., Pietu, G., Peschanski, M., and Martinat, C. (2011). Mutant human embryonic stem cells reveal neurite and synapse formation defects in type 1 myotonic dystrophy. Cell Stem Cell 8, 434-444.
152. Martin, J.P., and Bell, J. (1943). A pedigree of mental defect showing sexlinkage. J. Neurol. Psychiatry 6, 154-157.
153. Matsuura, T., Yamagata, T., Burgess, D.L., Rasmussen, A., Grewal, R.P., Watase, K., Khajavi, M., McCall, A.E., Davis, C.F., Zu, L., et al. (2000). Large expansion of the ATTCT pentanucleotide repeat in spinocerebellar ataxia type 10. Nat. Genet. 26, 191-194.
154. Maurer-Stroh, S., Dickens, N.J., Hughes-Davies, L., Kouzarides, T., Eisenhaber, F., and Ponting, C.P. (2003). The Tudor domain 'Royal Family': Tudor, plant Agenet, Chromo, PWWP and MBT domains. Trends Biochem. Sci. 28, 69-74.
155. Meijer, H., de Graaff, E., Merckx, D.M., Jongbloed, R.J., de Die-Smulders, C.E., Engelen, J.J., Fryns, J.P., Curfs, P.M., and Oostra, B.A. (1994). A deletion of 1.6 kb proximal to the CGG repeat of the FMR1 gene causes the clinical phenotype of the fragile X syndrome. Hum. Mol. Genet. 3, 615-620.
156. Menon, R.P., Soong, D., de Chiara, C., Holt, M.R., Anilkumar, N., and Pastore, A. (2012). The importance of serine 776 in Ataxin-1 partner selection: a FRET analysis. Sci. Rep. 2, 919.
157. Miller, J.W., Urbinati, C.R., Teng-Umnuay, P., Stenberg, M.G., Byrne, B.J., Thornton, C.A., and Swanson, M.S. (2000). Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. EMBO J. 19, 4439-4448.
158. Minamiyama, M., Katsuno, M., Adachi, H., Doi, H., Kondo, N., Iida, M., Ishigaki, S., Fujioka, Y., Matsumoto, S., Miyazaki, Y., et al. (2012). Naratriptan mitigates CGRP1-associated motor neuron degeneration caused by an expanded polyglutamine repeat tract. Nat. Med. 18, 1531-1538.
159. Mirkin, S.M. (2007). Expandable DNA repeats and human disease. Nature 447, 932-940.
160. Mori, K., Weng, S.-M., Arzberger, T., May, S., Rentzsch, K., Kremmer, E., Schmid, B., Kretzschmar, H.A., Cruts, M., Van Broeckhoven, C., et al. (2013). The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science. Published online February 7, 2013. http://dx.doi.org/10.1126/science.1232927.
161. Morrison, D.K. (2009). The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol. 19, 16-23.
162. Morton, N.E., Lalouel, J.M., Jackson, J.F., Currier, R.D., and Yee, S. (1980). Linkage studies in spinocerebellar ataxia (SCA). Am. J. Med. Genet. 6, 251-257.
163. Moseley, M.L., Zu, T., Ikeda, Y., Gao, W., Mosemiller, A.K., Daughters, R.S., Chen, G., Weatherspoon, M.R., Clark, H.B., Ebner, T.J., et al. (2006). Bidirectional expression of CUG and CAG expansion transcripts and intranuclear polyglutamine inclusions in spinocerebellar ataxia type 8. Nat. Genet. 38, 758-769.
164. Muddashetty, R.S., Kelić, S., Gross, C., Xu, M., and Bassell, G.J. (2007). Dysregulated metabotropic glutamate receptor-dependent translation of AMPA receptor and postsynaptic density-95 mRNAs at synapses in a mouse model of fragile X syndrome. J. Neurosci. 27, 5338-5348.
165. Muddashetty, R.S., Nalavadi, V.C., Gross, C., Yao, X., Xing, L., Laur, O., Warren, S.T., and Bassell, G.J. (2011). Reversible inhibition of PSD-95 mRNA translation by miR-125a, FMRP phosphorylation, and mGluR signaling. Mol. Cell 42, 673-688.
166. Mulders, S.A., van den Broek, W.J., Wheeler, T.M., Croes, H.J., van Kuik-Romeijn, P., de Kimpe, S.J., Furling, D., Platenburg, G.J., Gourdon, G., Thornton, C.A., et al. (2009). Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc. Natl. Acad. Sci. USA 106, 13915- 13920.
167. Nakamoto, M., Nalavadi, V., Epstein, M.P., Narayanan, U., Bassell, G.J., and Warren, S.T. (2007). Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors. Proc. Natl. Acad. Sci. USA 104, 15537-15542.
168. Nalavadi, V.C., Muddashetty, R.S., Gross, C., and Bassell, G.J. (2012). Dephosphorylation-induced ubiquitination and degradation of FMRP in dendrites: a role in immediate early mGluR-stimulated translation. J. Neurosci. 32, 2582-2587.
169. Napoli, I., Mercaldo, V., Boyl, P.P., Eleuteri, B., Zalfa, F., De Rubeis, S., Di Marino, D., Mohr, E., Massimi, M., Falconi, M., et al. (2008). The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP. Cell 134, 1042-1054.
170. Narayanan, U., Nalavadi, V., Nakamoto, M., Pallas, D.C., Ceman, S., Bassell, G.J., and Warren, S.T. (2007). FMRP phosphorylation reveals an immediateearly signaling pathway triggered by group I mGluR and mediated by PP2A. J. Neurosci. 27, 14349-14357.
171. Narayanan, U., Nalavadi, V., Nakamoto, M., Thomas, G., Ceman, S., Bassell, G.J., and Warren, S.T. (2008). S6K1 phosphorylates and regulates fragile X mental retardation protein (FMRP) with the neuronal protein synthesisdependent mammalian target of rapamycin (mTOR) signaling cascade. J. Biol. Chem. 283, 18478-18482.
172. Nedelsky, N.B., Pennuto, M., Smith, R.B., Palazzolo, I., Moore, J., Nie, Z., Neale, G., and Taylor, J.P. (2010). Native functions of the androgen receptor are essential to pathogenesis in a Drosophila model of spinobulbar muscular atrophy. Neuron 67, 936-952.
173. Nino, H.E., Noreen, H.J., Dubey, D.P., Resch, J.A., Namboodiri, K., Elston, R.C., and Yunis, E.J. (1980). A family with hereditary ataxia: HLA typing. Neurology 30, 12-20.
174. Nolin, S.L., Glicksman, A., Ding, X., Ersalesi, N., Brown, W.T., Sherman, S.L., and Dobkin, C. (2011). Fragile X analysis of 1112 prenatal samples from 1991 to 2010. Prenat. Diagn. 31, 925-931.
175. Oberle, I., Rousseau, F., Heitz, D., Kretz, C., Devys, D., Hanauer, A., Boue, J., Bertheas, M., and Mandel, J. (1991). Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome. Science 252, 1097-1102.
176. Orr, H.T., and Zoghbi, H.Y. (2007). Trinucleotide repeat disorders. Annu. Rev. Neurosci. 30, 575-621.
177. Orr, H.T., Chung, M.Y., Banfi, S., Kwiatkowski, T.J., Jr., Servadio, A., Beaudet, A.L., McCall, A.E., Duvick, L.A., Ranum, L.P., and Zoghbi, H.Y. (1993). Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat. Genet. 4, 221-226.
178. Pacey, L.K., Heximer, S.P., and Hampson, D.R. (2009). Increased GABA(B) receptor-mediated signaling reduces the susceptibility of fragile X knockout mice to audiogenic seizures. Mol. Pharmacol. 76, 18-24.
179. Parkesh, R., Childs-Disney, J.L., Nakamori, M., Kumar, A., Wang, E., Wang, T., Hoskins, J., Tran, T., Housman, D., Thornton, C.A., and Disney, M.D. (2012). Design of a bioactive small molecule that targets the myotonic dystrophy type 1 RNA via an RNA motif-ligand database and chemical similarity searching. J. Am. Chem. Soc. 134, 4731-4742.
180. Pastore, A., and Temussi, P.A. (2012). The two faces of Janus: functional interactions and protein aggregation. Curr. Opin. Struct. Biol. 22, 30-37.
181. Pieretti, M., Zhang, F.P., Fu, Y.H., Warren, S.T., Oostra, B.A., Caskey, C.T., and Nelson, D.L. (1991). Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 66, 817-822.
182. Powers, E.T., Morimoto, R.I., Dillin, A., Kelly, J.W., and Balch, W.E. (2009). Biological and chemical approaches to diseases of proteostasis deficiency. Annu. Rev. Biochem. 78, 959-991.
183. Qin, M., Kang, J., Burlin, T.V., Jiang, C., and Smith, C.B. (2005). Postadolescent changes in regional cerebral protein synthesis: an in vivo study in the FMR1 null mouse. J. Neurosci. 25, 5087-5095.
184. Qurashi, A., Li, W., Zhou, J.Y., Peng, J., and Jin, P. (2011). Nuclear accumulation of stress response mRNAs contributes to the neurodegeneration caused by Fragile X premutation rCGG repeats. PLoS Genet. 7, e1002102.
185. Qurashi, A., Liu, H., Ray, L., Nelson, D.L., Duan, R., and Jin, P. (2012). Chemical screen reveals small molecules suppressing fragile X premutation rCGG repeat-mediated neurodegeneration in Drosophila. Hum. Mol. Genet. 21, 2068-2075.
186. Reddy, S., Smith, D.B., Rich, M.M., Leferovich, J.M., Reilly, P., Davis, B.M., Tran, K., Rayburn, H., Bronson, R., Cros, D., et al. (1996). Mice lacking the myotonic dystrophy protein kinase develop a late onset progressive myopathy. Nat. Genet. 13, 325-335.
187. Renoux, A.J., and Todd, P.K. (2012). Neurodegeneration the RNA way. Prog. Neurobiol. 97, 173-189.
188. Renton, A.E., Majounie, E., Waite, A., Simón-Sánchez, J., Rollinson, S., Gibbs, J.R., Schymick, J.C., Laaksovirta, H., van Swieten, J.C., Myllykangas, L., et al.; ITALSGEN Consortium. (2011). A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257-268.
189. Reyniers, E., Wolff, G., Tariverdian, G., De Boulle, K., Storm, K., Kooy, R.F., and Willems, P.J. (1996). Severe mental retardation and macroorchidism without mutation in the FMR1 gene. Am. J. Med. Genet. 64, 408-412.
190. Riley, B.E., and Orr, H.T. (2006). Polyglutamine neurodegenerative diseases and regulation of transcription: assembling the puzzle. Genes Dev. 20, 2183-2192.
191. Rodriguez-Revenga, L., Madrigal, I., Pagonabarraga, J., Xuncla', M., Badenas, C., Kulisevsky, J., Gomez, B., and Mila', M. (2009). Penetrance of FMR1 premutation associated pathologies in fragile X syndrome families. Eur. J. Hum. Genet. 17, 1359-1362.
192. Ross, C.A., and Tabrizi, S.J. (2011). Huntington's disease: from molecular pathogenesis to clinical treatment. Lance. Neurol. 10, 83-98.
193. Santoro, M.R., Bray, S.M., and Warren, S.T. (2012). Molecular mechanisms of fragile X syndrome: a twenty-year perspective. Annu. Rev. Pathol. 7, 219-245.
194. Saudou, F., Finkbeiner, S., Devys, D., and Greenberg, M.E. (1998). Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95, 55-66.
195. Schmidt, B.J., Greenberg, C.R., Allingham-Hawkins, D.J., and Spriggs, E.L. (2002). Expression of X-linked bulbospinal muscular atrophy (Kennedy disease) in two homozygous women. Neurology 59, 770-772.
196. Schut, J.W. (1950). Hereditary ataxia. clinical study through six generations. Arch. Neurol. Psych. 63, 535-568.
197. Sellier, C., Rau, F., Liu, Y., Tassone, F., Hukema, R.K., Gattoni, R., Schneider, A., Richard, S., Willemsen, R., Elliott, D.J., et al. (2010). Sam68 sequestration and partial loss of function are associated with splicing alterations in FXTAS patients. EMBO J. 29, 1248-1261.
198. Serra, H.G., Duvick, L., Zu, T., Carlson, K., Stevens, S., Jorgensen, N., Lysholm, A., Burright, E., Zoghbi, H.Y., Clark, H.B., et al. (2006). RORa-mediated Purkinje cell development determines disease severity in adult SCA1 mice. Cell 127, 697-708.
199. Shelbourne, P., and Johnson, K. (1992). Myotonic dystrophy: another case of too many repeats? Hum. Mutat. 1, 183-189.
200. Sherman, S.L., Morton, N.E., Jacobs, P.A., and Turner, G. (1984). The marker (X) syndrome: a cytogenetic and genetic analysis. Ann. Hum. Genet. 48, 21-37.
201. Sherman, S.L., Jacobs, P.A., Morton, N.E., Froster-Iskenius, U., Howard-Peebles, P.N., Nielsen, K.B., Partington, M.W., Sutherland, G.R., Turner, G., and Watson, M. (1985). Further segregation analysis of the fragile X syndrome with special reference to transmitting males. Hum. Genet. 69, 289-299.
202. Siomi, H., Siomi, M.C., Nussbaum, R.L., and Dreyfuss, G. (1993). The protein product of the fragile X gene, FMR1, has characteristics of an RNA-binding protein. Cell 74, 291-298.
203. Sofola, O.A., Jin, P., Qin, Y., Duan, R., Liu, H., de Haro, M., Nelson, D.L., and Botas, J. (2007). RNA-binding proteins hnRNP A2/B1 and CUGBP1 suppress fragile X CGG premutation repeat-induced neurodegeneration in a Drosophila model of FXTAS. Neuron 55, 565-571.
204. Stefani, G., Fraser, C.E., Darnell, J.C., and Darnell, R.B. (2004). Fragile X mental retardation protein is associated with translating polyribosomes in neuronal cells. J. Neurosci. 24, 7272-7276.
205. Sugars, K.L., and Rubinsztein, D.C. (2003). Transcriptional abnormalities in Huntington disease. Trends Genet. 19, 233-238.
206. Sullivan, A.K., Marcus, M., Epstein, M.P., Allen, E.G., Anido, A.E., Paquin, J.J., Yadav-Shah, M., and Sherman, S.L. (2005). Association of FMR1 repeat size with ovarian dysfunction. Hum. Reprod. 20, 402-412.
207. Sutcliffe, J.S., Nelson, D.L., Zhang, F., Pieretti, M., Caskey, C.T., Saxe, D., and Warren, S.T. (1992). DNA methylation represses FMR-1 transcription in fragile X syndrome. Hum. Mol. Genet. 1, 397-400.
208. Sutherland, G.R. (1977). Fragile sites on human chromosomes: demonstration of their dependence on the type of tissue culture medium. Science 197, 265-266.
209. Sutherland, G.R., Haan, E.A., Kremer, E., Lynch, M., Pritchard, M., Yu, S., and Richards, R.I. (1991). Hereditary unstable DNA: a new explanation for some old genetic questions? Lancet 338, 289-292.
210. Takeyama, K., Ito, S., Yamamoto, A., Tanimoto, H., Furutani, T., Kanuka, H., Miura, M., Tabata, T., and Kato, S. (2002). Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron 35, 855-864.
211. Takeyama, K., Ito, S., Sawatsubashi, S., Shirode, Y., Yamamoto, A., Suzuki, E., Maki, A., Yamagata, K., Zhao, Y., Kouzmenko, A., et al. (2004). A novel genetic system for analysis of co-activators for the N-terminal transactivation function domain of the human androgen receptor. Biosci. Biotechnol. Biochem. 68, 1209-1215.
212. Tan, H., Xu, Z., and Jin, P. (2012). Role of noncoding RNAs in trinucleotide repeat neurodegenerative disorders. Exp. Neurol. 235, 469-475.
213. Taneja, K.L., McCurrach, M., Schalling, M., Housman, D., and Singer, R.H. (1995). Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues. J. Cell Biol. 128, 995-1002.
214. Tassone, F., Hagerman, R.J., Taylor, A.K., Gane, L.W., Godfrey, T.E., and Hagerman, P.J. (2000). Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. Am. J. Hum. Genet. 66, 6-15.
215. Tassone, F., Iwahashi, C., and Hagerman, P.J. (2004). FMR1 RNA within the intranuclear inclusions of fragile X-associated tremor/ataxia syndrome (FXTAS). RNA Biol. 1, 103-105.
216. Timchenko, L.T., Miller, J.W., Timchenko, N.A., DeVore, D.R., Datar, K.V., Lin, L., Roberts, R., Caskey, C.T., and Swanson, M.S. (1996). Identification of a (CUG)n triplet repeat RNA-binding protein and its expression in myotonic dystrophy. Nucleic Acids Res. 24, 4407-4414.
217. Timchenko, N.A., Cai, Z.J., Welm, A.L., Reddy, S., Ashizawa, T., and Timchenko, L.T. (2001). RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1. J. Biol. Chem. 276, 7820-7826.
218. Tsai, C.-C., Kao, H.-Y., Mitzutani, A., Banayo, E., Rajan, H., McKeown, M., and Evans, R.M. (2004). Ataxin 1, a SCA1 neurodegenerative disorder protein, is functionally linked to the silencing mediator of retinoid and thyroid hormone receptors. Proc. Natl. Acad. Sci. USA 101, 4047-4052.
219. Tsuda, H., Jafar-Nejad, H., Patel, A.J., Sun, Y., Chen, H.K., Rose, M.F., Venken, K.J., Botas, J., Orr, H.T., Bellen, H.J., and Zoghbi, H.Y. (2005). The AXH domain of Ataxin-1 mediates neurodegeneration through its interaction with Gfi-1/Senseless proteins. Cell 122, 633-644.
220. Udd, B., and Krahe, R. (2012). The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol. 11, 891-905.
221. Van Dam, D., Errijgers, V., Kooy, R.F., Willemsen, R., Mientjes, E., Oostra, B.A., and De Deyn, P.P. (2005). Cognitive decline, neuromotor and behavioural disturbances in a mouse model for fragile-X-associated tremor/ataxia syndrome (FXTAS). Behav. Brain Res. 162, 233-239.
222. Verheij, C., Bakker, C.E., De Graaff, E., Keulemans, J., Willemsen, R., Verkerk, A.J., Galjaard, H., Reuser, A.J., Hoogeveen, A.T., and Oostra, B.A. (1993). Characterization and localization of the FMR-1 gene product associated with fragile X syndrome. Nature 363, 722-724.
223. Verkerk, A.J.M.H., Pieretti, M., Sutcliffe, J.S., Fu, Y.H., Kuhl, D.P., Pizzuti, A., Reiner, O., Richards, S., Victoria, M.F., Zhang, F.P., et al. (1991). Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65, 905-914.
224. Wang, Y.C., Lin, M.L., Lin, S.J., Li, Y.C., and Li, S.Y. (1997). Novel point mutation within intron 10 of FMR-1 gene causing fragile X syndrome. Hum. Mutat. 10, 393-399.
225. Wang, E.T., Cody, N.A., Jog, S., Biancolella, M., Wang, T.T., Treacy, D.J., Luo, S., Schroth, G.P., Housman, D.E., Reddy, S., et al. (2012). Transcriptome-wide regulation of pre-mRNA splicing and mRNA localization by muscleblind proteins. Cell 150, 710-724.
226. Warf, M.B., Nakamori, M., Matthys, C.M., Thornton, C.A., and Berglund, J.A. (2009). Pentamidine reverses the splicing defects associated with myotonic dystrophy. Proc. Natl. Acad. Sci. USA 106, 18551-18556.
227. Watase, K., Weeber, E.J., Xu, B., Antalffy, B., Yuva-Paylor, L., Hashimoto, K., Kano, M., Atkinson, R., Sun, Y., Armstrong, D.L., et al. (2002). A long CAG repeat in the mouse Sca1 locus replicates SCA1 features and reveals the impact of protein solubility on selective neurodegeneration. Neuron 34, 905-919.
228. Wheeler, T.M., Sobczak, K., Lueck, J.D., Osborne, R.J., Lin, X., Dirksen, R.T., and Thornton, C.A. (2009). Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science 325, 336-339.
229. Wheeler, T.M., Leger, A.J., Pandey, S.K., MacLeod, A.R., Nakamori, M., Cheng, S.H., Wentworth, B.M., Bennett, C.F., and Thornton, C.A. (2012). Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 488, 111-115.
230. Willemsen, R., Hoogeveen-Westerveld, M., Reis, S., Holstege, J., Severijnen, L.A., Nieuwenhuizen, I.M., Schrier, M., van Unen, L., Tassone, F., Hoogeveen, A.T., et al. (2003). The FMR1 CGG repeat mouse displays ubiquitin-positive intranuclear neuronal inclusions; implications for the cerebellar tremor/ataxia syndrome. Hum. Mol. Genet. 12, 949-959.
231. Williams, A.J., and Paulson, H.L. (2008). Polyglutamine neurodegeneration: protein misfolding revisited. Trends Neurosci. 31, 521-528.
232. Xia, H., Mao, Q., Eliason, S.L., Harper, S.Q., Martins, I.H., Orr, H.T., Paulson, H.L., Yang, L., Kotin, R.M., and Davidson, B.L. (2004). RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat. Med. 10, 816-820.
233. Yakura, H., Wakisaka, A., Fujimoto, S., and Itakura, K. (1974). Letter: Hereditary ataxia and HL-A. N. Engl. J. Med. 291, 154-155.
234. Yrigollen, C.M., Durbin-Johnson, B., Gane, L., Nelson, D.L., Hagerman, R., Hagerman, P.J., and Tassone, F. (2012). AGG interruptions within the maternal FMR1 gene reduce the risk of offspring with fragile X syndrome. Genet. Med. 14, 729-736.
235. Yu, D., Pendergraff, H., Liu, J., Kordasiewicz, H.B., Cleveland, D.W., Swayze, E.E., Lima, W.F., Crooke, S.T., Prakash, T.P., and Corey, D.R. (2012). Singlestranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell 150, 895-908.
236. Yue, S., Serra, H., Zoghbi, H.Y., and Orr, H.T. (2001). The spinocerebellar ataxia type 1 protein, ataxin-1, has RNA-binding activity that is inversely affected by the length of its polyglutamine tract. Hum. Mol. Genet. 10, 25-30.
237. Zang, J.B., Nosyreva, E.D., Spencer, C.M., Volk, L.J., Musunuru, K., Zhong, R., Stone, E.F., Yuva-Paylor, L.A., Huber, K.M., Paylor, R., et al. (2009). A mouse model of the human Fragile X syndrome I304N mutation. PLoS Genet. 5, e1000758.
238. Zhong, N., Ju, W., Pietrofesa, J., Wang, D., Dobkin, C., and Brown, W.T. (1996). Fragile X "gray zone"alleles: AGG patterns, expansion risks, and associated haplotypes. Am. J. Med. Genet. 64, 261-265.
239. Zhuchenko, O., Bailey, J., Bonnen, P., Ashizawa, T., Stockton, D.W., Amos, C., Dobyns, W.B., Subramony, S.H., Zoghbi, H.Y., and Lee, C.C. (1997). Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. Nat. Genet. 15, 62-69.
240. Zoghbi, H.Y., and Bear, M.F. (2012). Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities. Cold Spring Harb. Perspect. Biol. 4. http://dx.doi.org/10.1101/cshperspect. a009886.
241. Zu, T., Duvick, L.A., Kaytor, M.D., Berlinger, M.S., Zoghbi, H.Y., Clark, H.B., and Orr, H.T. (2004). Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice. J. Neurosci. 24, 8853-8861.
242. Zu, T., Gibbens, B., Doty, N.S., Gomes-Pereira, M., Huguet, A., Stone, M.D., Margolis, J., Peterson, M., Markowski, T.W., Ingram, M.A., et al. (2011). Non-ATG-initiated translation directed by microsatellite expansions. Proc. Natl. Acad. Sci. USA 108, 260-265.